Fulgent Genetic (NASDAQ:FLGT)‘s stock had its “overweight” rating restated by investment analysts at Piper Jaffray Companies in a report released on Wednesday. They currently have a $7.00 target price on the stock, down from their previous target price of $10.00. Piper Jaffray Companies’ target price suggests a potential upside of 24.11% from the company’s previous close.

A number of other research firms have also recently commented on FLGT. Zacks Investment Research upgraded shares of Fulgent Genetic from a “sell” rating to a “hold” rating in a research note on Thursday, April 27th. Credit Suisse Group decreased their target price on shares of Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday.

Fulgent Genetic (NASDAQ FLGT) traded up 4.64% during mid-day trading on Wednesday, hitting $5.64. 42,194 shares of the stock traded hands. The stock’s market cap is $99.78 million. Fulgent Genetic has a 1-year low of $4.49 and a 1-year high of $13.90. The company’s 50 day moving average price is $6.44 and its 200-day moving average price is $9.15.

Fulgent Genetic (NASDAQ:FLGT) last posted its quarterly earnings data on Monday, August 7th. The company reported $0.02 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.02. The company had revenue of $4.64 million for the quarter, compared to the consensus estimate of $5.03 million. Fulgent Genetic had a negative net margin of 0.42% and a negative return on equity of 0.02%. Analysts predict that Fulgent Genetic will post $0.16 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/fulgent-genetic-nasdaqflgt-stock-rating-reaffirmed-by-piper-jaffray-companies/1466768.html.

In related news, insider Ming Hsieh acquired 30,000 shares of Fulgent Genetic stock in a transaction dated Tuesday, June 13th. The shares were purchased at an average price of $4.98 per share, for a total transaction of $149,400.00. Following the completion of the transaction, the insider now directly owns 6,459,944 shares in the company, valued at approximately $32,170,521.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN boosted its stake in Fulgent Genetic by 2,046.0% in the first quarter. Wells Fargo & Company MN now owns 10,730 shares of the company’s stock valued at $118,000 after buying an additional 10,230 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in Fulgent Genetic during the first quarter valued at about $122,000. Blair William & Co. IL bought a new stake in Fulgent Genetic during the first quarter valued at about $287,000. Scholtz & Company LLC boosted its stake in Fulgent Genetic by 50.3% in the first quarter. Scholtz & Company LLC now owns 266,705 shares of the company’s stock valued at $2,912,000 after buying an additional 89,205 shares during the last quarter. Finally, William Blair Investment Management LLC boosted its stake in Fulgent Genetic by 10.4% in the second quarter. William Blair Investment Management LLC now owns 640,219 shares of the company’s stock valued at $4,091,000 after buying an additional 60,508 shares during the last quarter. Hedge funds and other institutional investors own 19.75% of the company’s stock.

Fulgent Genetic Company Profile

Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.

Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with Analyst Ratings Network's FREE daily email newsletter.